Spectrum Pharma (SPPI) Reports Q3 EPS of $0.00
- Wall St rallies on bright earnings, megacaps' support
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Spectrum Pharmaceuticals Provides Third Quarter Financial and Pipeline Update
November 3, 2016 4:06 PM EDTFinancial Update: Q3 revenues were $33.4 million, including $30.3 million in product sales, with recently launched drug EVOMELA® (melphalan) for injection contributing $5.9 million. The Company ended the quarter with Cash and Cash Equivalents of $171.9 million. Earnings Call Update: Spectrum is re-examining the accounting treatment of the 2013 acquisition of the rights to CE Melphalan from Ligand Pharmaceuticals. This re-examination is not expected to impact reported revenue or cash balance for this or prior periods. The previously scheduled earnings conference call for the third quarter 2016 will not take place today and the Company plans to release full... More